This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

About the Drug Discovery, Development & Evaluation Affinity Group

The Drug Discovery, Development & Evaluation Affinity Group serves members with interests in all aspects from drug discovery to prescribed use including target identification, drug development, safety pharmacology, conduct of medical research and clinical trials, approval and licensing. This includes all areas of the drug discovery and development process including ‘omics approaches, drug-screening, molecular, cellular, systems or whole organism approaches, pharmacokinetics, pharmacodynamics, pharmacoepidemiology, pharmacoeconomics, clinical testing, drug regulation and registration, adverse drug reactions along with all aspects relevant to the post-market distribution and utilisation of drugs. Drug discovery also serves members with interests in natural products and nutraceuticals.

Contact the co-chairs


David Kendall

David  is the Chief Scientific Officer of PharmNovo AB/UK, a small drug discovery company focussed on the development of chronic pain medicines. He is Professor Emeritus of Pharmacology at the University of Nottingham and Visiting Professor at Liverpool John Moores University School of Pharmacy and Biomolecular Sciences.

Sarah Nickolls

Sarah is a group leader in the Screening Profiling and Mechanistic Biology department at GlaxoSmithKline. She has a strong background in drug discovery having previously worked at Pfizer and Neurocrine Biosciences and has both clinical and preclinical experience. Her PhD on GPCR agonist bias was supervised by Professor Philip Strange.

Join the Group

Keep up to date with developments in your field by signing up to any of the affinity groups.